Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Threshold, a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, has reported net loss of $8.33m for the first quarter ended 31 March 2011, or $0.23 loss per diluted share, as compared to $5.96m or $0.18 loss per diluted share for the same period in 2010.
Subscribe to our email newsletter
The company’s loss from operations was $7.39m, compared to $5.76m for the same period last year.
Total operating expenses for the first quarter ended 31 March 2011 were $7.39m, as compared to $5.76m for the same period in 2010.
Research and development expenses were $6.1m for the first quarter of 2011 compared to $4.5m for the first quarter of 2010.
The increase in research and development expenses primarily reflects an increase in clinical trial expenses related to anticancer agent TH-302.